Cite
HARVARD Citation
Erbe, A. et al. (2023). KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group. Journal for immunotherapy of cancer. 11 (2), p. . [Online].